Protalix BioTherapeutics reported second quarter 2026 financial results and a business update. Revenues from selling goods increased to $19.8 million in Q2 2026, up from $15.4 million in the prior year period, driven by Elfabrio sales. Total revenue for the first half of 2026 reached $53.6 million, including a $25.0 million milestone payment from Chiesi, compared to $25.8 million in the same period last year. The company achieved net income of $22.1 million for the six months ended June 30, 2026, or $0.27 per share diluted. Cash and equivalents stood at $40.7 million as of June 30, 2026. Protalix reaffirmed its full-year 2026 total revenue guidance of $78.0 million to $83.0 million. The company operates in the biopharmaceutical industry, focusing on the discovery and commercialization of enzyme replacement therapies for rare diseases.

Protalix BioTherapeutics, Inc. held its 2026 Annual Meeting of Stockholders on June 25, 2026. Shareholders elected eight directors and ratified Kesselman & Kesselman as the independent registered public accounting firm for the 2026 fiscal year. Additionally, stockholders approved an amended and restated 2006 Stock Incentive Plan, which increases the number of common stock shares available under the plan from 17,475,171 to 20,975,171. The meeting also included a non-binding advisory vote on executive compensation. Protalix BioTherapeutics is a biotechnology company.